Skip to main content
Figure 4 | Molecular Pain

Figure 4

From: Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery

Figure 4

The mixed cannabinoid CB 1 /CB 2 agonist WIN55,212-2 (0.5 mg/kg/day s.c.) and the CB 2 -preferring agonist, AM1710 (3.2 mg/kg/day s.c.) suppressed the development of both a. mechanical and b. cold allodynia associated with paclitaxel treatment. No antinociception was observed in cremophor animals treated with either cannabinoid agonist in response to mechanical or cold stimulation.*P <0.05, **P <0.01,***P <0.001 vs. Cremophor-Vehicle, # P < 0.05, ## P <0.01, ### P <0.001 All conditions vs. Taxol-Vehicle (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.

Back to article page